Press Release 2012

A placebo-controlled, randomized double-blind clinical trial published in Phytotherapy Research titled Effects of Supplementation with Curcuminoids on Dyslipidemia in Obese Patients: A Randomized Crossover Trial (Mohammadi et al, 2012) reported that Sabinsa's Curcumin C3 Complex® led to a significant reduction in serum triglycerides concentration in a randomized crossover clinical trial.

Abnormal amount of lipids in the blood is a leading risk factor for cardiovascular disease. It is also a common feature of obesity and metabolic syndrome, and precedes Alzheimer’s disease.

This study investigated the lipid lowering activity of curcumin in obese individuals. Thirty participants received curcuminoids (1g/day) with natural bioavailability-enhancer BioPerine®, or placebo in a randomized, double-blind, placebo-controlled, crossover trial. Serum concentrations of total cholesterol, triglycerides, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol, together with anthropometric parameters and high-sensitivity C-reactive protein were measured before and after each treatment period.

Serum triglycerides were significantly reduced following curcumin supplementation (first period 105.7 -> 95.1 mg/dL, and second period 120.7 -> 104.7 mg/dL). The findings of the present study indicated that curcuminoids supplementation (1g/day for 30 days) leads to a significant reduction in serum triglycerides concentrations. The result of this clinical trial is also a good confirmation of systemic effect of Curcumin C3 Complex®.

To read the article:

For more information on Sabinsa’s Curcumin,


  • Sabinsa Corporation
    20 Lake Drive
    East Windsor
    NJ 08520, USA

  • +1 732 777 1111
  • +1 732 777 1443


Certificate Logos Certificate Logos
Certificate Logos Certificate Logos